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Background: Small-for-gestational age (SGA) at birth increases risk of development of adult obesity and insulin
resistance. A model of SGA rat offspring has been shown to exhibit increased adipose tissue expression of a key
adipogenic transcription factor, peroxisome proliferator-activated receptor gamma (PPARγ), and increased fatty acid
de novo synthesis during the nursing period, prior to onset of obesity. PPARγ agonists have been studied for
potential use in the prevention of insulin resistance. Moreover, SGA adipocytes exhibit age-dependent differences in
lipogenesis as mediated by PPARγ. The effects of PPARγ modulators on lipogenic gene expression and de novo
lipogenesis on the age-dependent changes in SGA adipocytes are not known. The objectives of this study were: 1)
to determine the adipogenic and lipogenic potential in SGA adipocytes at postnatal day 1 (p1) and day 21 (p21), 2)
to determine how the PPARγ activator- and repressor-ligands affect the lipogenic potential, and 3) to determine the
fatty acid metabolic response to PPARγ activator-ligand treatment.
Methods: Primary adipocyte cultures from p1 and p21 SGA and Control male offspring were established from a
known maternal food-restriction model of SGA. Cell proliferation and Oil Red O (ORO) staining were quantified.
Adipocytes were treated with increasing doses of rosiglitazone or bisphenol-A diglycidyl ether (BADGE). PPARγ and
SREBP1 protein expression were determined. De novo lipogenesis with rosiglitazone treatment at p21 was studied
using 50% U13C-glucose and gas chromatography/mass spectrometry.
Results: At p1 and p21, SGA demonstrated increased cell proliferation and increased ORO staining. At p21, SGA
demonstrated increased lipogenic gene expression and increased glucose-mediated fatty acid de novo synthesis
compared with Controls. In response to rosiglitazone, SGA adipocytes further increased glucose utilization for fatty
acid synthesis. SGA lipogenic gene expression demonstrated resistance to BADGE treatment.
Conclusions: SGA adipocytes exhibit an enhanced adipogenic and lipogenic potential in early postnatal life. By
p21, SGA demonstrated resistance to PPARγ repressor-ligand treatment, and selective response to high dose PPARγ
activator-ligand treatment in adipogenic and lipogenic gene expression. p21 SGA adipocytes revealed increased
fatty acid de novo synthesis through a complex relationship with glucose metabolism.
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Human epidemiological studies have shown that small-
for-gestational age (SGA) newborns demonstrate
increased risk for adult obesity and metabolic syndrome
[1,2]. Animal studies have effectively replicated this asso-
ciation [3-5] in that maternal undernutrition during rat
pregnancy results in SGA. When these SGA pups are
nursed normally, they exhibit hyperphagia [6], catch-up
growth, and develop adult obesity and insulin resistance
[4,5]. The increased adiposity has been attributed to
“programmed” upregulation of the adipogenic transcrip-
tion factor peroxisome proliferator-activated receptor γ
(PPARγ). SGA newborns demonstrate increased PPARγ
expression prior to the onset of obesity [7]. The down-
stream lipid target of PPARγ is a lipogenic transcription
factor, SREBP1c (sterol regulatory element binding pro-
tein 1), which in turn induces expression of lipogenic
enzyme fatty acid synthase (FASN) [8]. Both SREBP1c
and FASN are upregulated in SGA adipose tissue at the
end of the nursing period (p21) [7]. Hence, modulation
of PPARγ may provide a therapeutic strategy in prevent-
ing adiposity in SGA offspring.
As an enhancer of adipocyte differentiation and lipid
accumulation, PPARγ has been studied as a target for
pharmacological therapy. Rosiglitazone, which is a mem-
ber of the thiazolidinedione (TZD) class of drugs, is a se-
lective ligand of PPARγ. It has the ability to activate
PPARγ, and hence induce adipocyte differentiation in cell
culture models and promote weight gain in rodents and
humans [9,10]. Recent studies have further shown that
rosiglitazone may directly induce expression of PPARγ
[11,12]. Although rosiglitazone causes weight gain, long-
term treatment leads to a smaller adipocyte phenotype,
suggesting changes in the metabolic pathways leading
to fat accumulation [13]. While studies have demon-
strated that TZDs increase free fatty acid uptake in adi-
pocytes [14,15], the effects of TZDs on endogenous
fatty acid synthesis have not been well-studied. Con-
versely, bisphenol-A diglycidyl ether (BADGE), a select-
ive PPARγ antagonist, has shown the ability to prevent
adipocyte differentiation in vitro [16]. BADGE also has
the ability to interfere with rosiglitazone-mediated ef-
fects on PPARγ since both PPARγ modulators (rosigli-
tazone and BADGE) bind at the ligand-binding domain
[16,17].
Consistent with upregulated PPARγ, SREBP1c, and
lipogenic target genes, our rat model of SGA offspring
exhibits increased adipose tissue fatty acid de novo syn-
thesis as early as 3 weeks of age [3]. Thus, SGA offspring
demonstrate upregulation of the adipogenesis signaling
cascade and enhanced adipose tissue lipogenesis prior to
development of an obese phenotype. We hypothesized
that the increased adipogenic potential of SGA offspring
is an intrinsic cellular response, which contributes toenhanced lipogenesis. Furthermore, we hypothesized
that the enhanced lipogenesis is facilitated by increased
glucose-mediated fatty acid synthesis. We addressed our
hypotheses by utilizing primary adipocyte cultures from
1 day old (p1) and 3 week old (p21) SGA offspring. We
further examined the effect of PPARγ modulators, rosi-
glitazone (activator-ligand) and BADGE (repressor-lig-
and) on the lipogenic targets downstream of PPARγ. To
delineate the specific effects of rosiglitazone treatment
in the fatty acid synthesis pathways, we studied
rosiglitazone-stimulated glucose utilization toward de




Studies received approval from the Animal Care Com-
mittee at the Los Angeles Biomedical Research Institute
at Harbor-UCLA and were in accordance with the
American Accreditation Association of Laboratory Care.
A description of the maternal food-restriction rat
model has been previously published [4]. In brief, first-
time pregnant Sprague–Dawley rats (Charles River La-
boratories, Hollister, CA) were housed in an animal fa-
cility with controlled 12/12 hour light/dark cycles, and
constant temperature and humidity conditions. On day
10 of gestation (e10), dams were either given a standard
laboratory ad libitum chow diet (Lab Diet 5001, Brent-
wood, Missouri) to yield normal size pups, or were 50%
food-restricted to produce SGA pups. Dams continued
the assigned diets during pregnancy and lactation. After
birth, on day 1 (p1), individual pups were weighed. To
standardize nursing, litters were culled to 8 pups per
dam (4 males and 4 females) to include the offspring of
median weights. SGA offspring were cross-fostered to
ad libitum-fed control dams. To control for cross-
fostering technique, the control pups were also cross-
fostered to control dams.
Male offspring (n = 6 at each age per group) were
decapitated at postnatal day 1 (p1), or given an overdose
of pentobarbital (200 mg/kg intraperitoneally) at day 21
(p21), then the adipose tissue was collected. Subcutane-
ous adipose tissue was collected at p1 due to minimal
retroperitoneal adipose tissue availability at this age.
Retroperitoneal adipose tissue was collected at p21 be-
cause previous data on this model already demonstrated
abnormalities in this tissue [3].
Primary adipocyte cell cultures
Pooled adipose tissue from p1 or p21 animals was
minced, and digested with collagenase type II (5000U/g)
in Krebs-Ringer solution for 30 min at 37 °C, filtered
through 200 μm mesh nylon filter, then centrifuged at
500 x g for 5 minutes. The cells were resuspended in
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medium (DMEM) (Invitrogen) with 10% fetal bovine
serum (FBS) and 1% Antibiotic-Antimycotics (Invitro-
gen), seeded into flasks and incubated at 37 °C with 5%
CO2 until confluent. For all experiments except for the
cell proliferation assay, adipocyte differentiation was
induced with dexamethasone (1 μM), methylisobutyl-
xanthine (0.1 mM), and insulin (10 μg/ml) for 10 days.
Cell proliferation assay
Preadipocytes from p1 and p21 Control and SGA male off-
spring were isolated as above, and seeded (1 x 104 cells) in
DMEM supplemented with 10% FBS and 1% Antibiotic-
Antimycotics. After 24 hours, 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT, from Sigma) was
added to each well, then cells were incubated at 37 °C. The
remaining MTT was removed, the dye crystals were solubi-
lized in isopropanol, and the absorbance was read by spec-
trophotometry at 570 nm wavelength (Perkin Elmer 1420
Mulitlabel counter VICTOR3 spectrophotometer).
Oil red O (ORO) staining and assay
Preadipocytes were seeded (1 x 104 cells) and cells were
allowed to differentiate into mature adipocytes after in-
duction as above. Cells were subsequently fixed with 4%
paraformaldehyde, stained with 0.5% ORO, mounted onto
slides with Vectashield mounting medium with 4',6-diami-
dino-2-phenylindole (DAPI; Vector) and images (40X
magnification) captured (Zeiss Axioskop 40 microscope
with Axiocam HRc camera).
For quantification, adipocytes stained with ORO were
dried for 1 hour at 37 °C, incubated with a fixed volume
of isopropanol for 20 minutes to elute the ORO, and ab-
sorbance measured at 570 nm.
PPARγ modulation studies
After differentiation, adipocytes at p1 and p21 were
incubated in high glucose DMEM with rosiglitazone
(Sigma) at 0, 1 or 10 μM concentration, or with BADGE
(Alexis Biochemicals) at 0, 1 or 10 μM concentration.
Untreated cells received DMSO for 24 hours. Protein
was extracted by sonication in RIPA buffer with
phosphodiesterase inhibitor and EDTA, then the con-
centration was measured using the BCA Protein Assay
(Pierce). 20 μg of protein was loaded on a precast
BioRad BisTris gel, then transferred to nitrocellulose
membranes. Non-specific binding was blocked by non-
fat milk. Primary antibodies were applied overnight,
membranes washed, and species-appropriate secondary
antibodies applied. Autoradiography of membranes with
chemiluminescence (Pierce Super Signal West Pico
Chemiluminescence kit) was carried out in a darkroom.
After stripping and washing of the original membrane, a
primary antibody suitable for use as an internal controlwas applied, followed by a secondary antibody and
chemiluminescence. Densitometry was performed on the
protein of interest and band intensities were normalized
to those of the corresponding control. The following are
the antibodies used and their respective sources: PPARγ
(Affinity Bio Reagents, AB Cam), SREBP1 (Santa Cruz),
FASN (Santa Cruz).
Stable isotope fatty acid metabolism studies
Primary adipocytes from p21 male RP fat were isolated
and differentiated as above. For 24 hours following dif-
ferentiation, Control and SGA adipocytes received
DMSO or rosiglitazone 10 μM (n= 3 each group). 50%
of the glucose in the high glucose DMEM was com-
prised of U13C-glucose as a tracer. After this experimen-
tal period, cells from each flask were collected as pellets
for fatty acid analysis and Western blotting.
Fatty acid extractions
Total fatty acids (from phospholipids, triglycerides, cho-
lesteryl esters and free fatty acids) were extracted from
adipocyte cell pellets, using a method by Lowenstein
et al. [18]. In summary, adipocytes were saponified in
200-proof ethanol and 30% KOH (w/v) in a 1:1 volume
overnight on a 70 °C heating block. Samples were acid-
ified with HCl, fatty acids were extracted three times
with petroleum ether, then air dried. Fatty acids were
derivatized as methyl esters using 0.5 N methanolic HCl,
dried under a nitrogen stream, and subsequently recon-
stituted with hexane for gas chromatography/mass spec-
trometry (GC/MS) analysis.
Gas chromatography/mass spectrometry
GC/MS analysis was carried out using a Hewlett-
Packard model 5973 selective mass detector connected
to a model 6890 gas chromatograph. Fatty acids were
analyzed as their methyl esters. Fatty acids were sepa-
rated on the gas chromatograph with a Bpx70 column
(30-m length, 250-μm diameter, 0.25-μm film thickness)
from SGE, Inc. (Austin, TX). The GC conditions were:
helium flow rate, 1 ml/min; initial oven temperature,
150 °C; temperature was programmed to increase at
3 °C/min to a final temperature of 221 °C. The expected
retention times under these conditions for palmitate, pal-
mitoleate, stearate, oleate, and vaccenate (the major fatty
acids of interest in this study) were as follows: 6.5, 7.1, 9.4,
10.0, and 10.1 min, respectively. Mass spectra of fatty
acids were acquired using electron impact ionization
and selective ion monitoring. Ion clusters monitored
for isotopomer quantitation were mass-to-charge ratio
(m/z) 270 for palmitate (16:0), m/z 268 for palmitole-
ate (16:1), m/z 298 for stearate (18:0), m/z 264 for
oleate (18:1n-9) and vaccenate (18:1n-7). Distribution
of the mass isotopomers was determined from the
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Lee et al. [19] that corrects for the contribution of deriva-
tizing agent and 13 C natural abundance to the mass
isotopomer distribution of the compound of interest.
Each compound of interest is composed of the sum
of isotopomer peaks within a cluster. The resulting mass
isotopomer distribution was expressed in molar fractions
(m0, m1, m2, m3, etc.) corresponding to the fraction of
molecules that contain 0, 1, 2, 3, . . .13C substitutions.
Fatty acid profile
The overall fatty acid profile was determined by calcula-
tion of the area under the respective gas chromatogram
peaks for each main fatty acid of interest as a percent of
total fatty acids. The percent of total for each fatty acid
represents the total relative abundance (labeled plus
unlabeled).
Fraction of new synthesis (FNS) over 24 hours, acetyl-CoA
enrichment, and percent glucose contribution to de novo
synthesis
The FNS represents the new fatty acids produced during
the 24 hour experimental period, and is expressed as a
percentage of total for each fatty acid. M+ 2 and M+4
isotopomers result from U13C-glucose incorporation
into palmitate in de novo lipogenesis, thereby allowing
calculation of the precursor acetyl-CoA enrichment
from the consecutive mass isotopomer ratio m4/m2, and
subsequent determination of the FNS. The FNS of stear-
ate was determined from the m6/m4 ratio to minimize
potential chain elongation effects on the m4/m2 ratio.
Percent contribution to de novo lipogenesis (percent
contribution to de novo synthesis of palmitate, the main
product of de novo lipogenesis) from glucose was calcu-
lated based on the acetyl-CoA enrichment, and 50% iso-
tope enrichment of the medium glucose [20].
Medium glucose determination
Glucose concentration was determined on cell culture
medium using the Glucose HK Assay Kit (Sigma)
according the manufacturer’s instructions, using spectro-
photometry. Glucose content was calculated for the vol-
ume of medium used for each culture. Glucose
consumption from the medium was then determined in-
directly by subtracting the glucose content of the post-
treatment medium from the glucose content of the ori-
ginal pretreatment medium.
Tricarboxylic acid (TCA) cycle studies
To determine the contribution of the TCA cycle to fatty
acid synthesis, the relative contributions from the pyruvate
carboxylase (PC) and pyruvate dehydrogenase (PDH)
pathways were studied through determination of glutam-
ate fragment enrichment [21]. Pyruvate carboxylase (PC)contributes toward production of gluconeogenic precur-
sors through formation of oxaloacetate (OAA). PDH activ-
ity produces acetyl-CoA which can be used for fatty acid
synthesis through formation of citrate. Downstream of cit-
rate, glutamate equilibrates with α-ketoglutarate [22], and
reflects different fragment enrichment patterns based on
contributions from the PC and PDH pathways. Glutamate
was extracted from 1 ml samples of medium by previously
published methods using ion exchange columns [21,23].
Glutamate was derivatized as its n-trifluoroacetyl-n-buty-
lester and analyzed by GC/MS using electron impact
ionization. Two fragments were identified and the Σmn
enrichment (fraction of 13C atoms/mole) was determined
for each. The fragments were analyzed for the m2 isotopo-
mer enrichment (m2): m/z 152, representing the C2-C4
fragment (pyruvate carboxylase), and m/z 198, represent-
ing the C2-C5 fragment (pyruvate carboxylase + pyruvate
dehydrogenase). The pyruvate carboxylase/pyruvate de-
hydrogenase (PC/PDH) ratio was determined by calculat-
ing (m2 of 152)/[(m2 of 198)-(m2 of 152)] to evaluate for
differences in glucose metabolism via pyruvate entrance
into the TCA cycle. When entry of glucose into the TCA
cycle via PC and PDH are equal, the PC/PDH ratio is ap-
proximately 1. A decrease in the ratio suggests a relative
increase in PDH activity, while an increase in the ratio
suggests increased PC activity.
Statistical analysis
Statistical analysis was performed using SigmaStat soft-
ware. Comparisons were made by ANOVA 1) within
each group (Control or SGA) between the basal state
and the treated states with increasing dose of PPARγ
modulator, and also 2) between the two groups under
the same treatment conditions. Fatty acid profile and
stable isotope data were analyzed among treated and un-
treated Control and SGA groups by two-way ANOVA,
followed by pair-wise multiple comparisons using
Tukey’s test. Parametric data are presented as mean ± the
standard error of the mean. Data that failed normality
testing was analyzed by Kruskal-Wallis ANOVA on
ranks, with pair-wise comparisons using Mann–Whitney
testing. The non-parametric data (individual PC and
PDH data) are therefore presented as the median with
the 25-75% interquartile ranges. For comparison pur-
poses, the PC/PDH ratio is also presented as the median
with the 25-75% interquartile ranges.
Results
Preadipocyte proliferation and adipocyte oil red O
staining
At both p1 and p21, SGA demonstrated increased prea-
dipocyte proliferation and increased adipocyte lipid con-
tent as compared to Controls. With age, preadipocyte
proliferation decreased while adipocyte lipid ORO
400A *
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**Adipogenic and lipogenic transcription factors at p1
At baseline, unstimulated SGA adipocytes demon-
strated increased PPARγ protein expression, but com-
parable SREBP1 expression as compared to Controls
(Figures 3A).
With rosiglitazone, Control and SGA adipocytes
responded to low and high doses with marked increases in
PPARγ, and moderate, though significant, increases in
SREBP1 (Figure 3A). The responses to both doses were
similar in each group. Furthermore, SGA adipocytes
maintained higher expression of PPARγ, but similar
SREBP1 expression as the Control adipocytes.Figure 2 Oil Red O (ORO) staining in Control and SGA
adipocytes. Gray bars represent Controls, and white bars represent
SGA. (A) SGA adipocytes exhibit greater triglyceride accumulation
than Controls at both p1 and p21. (B) SGA adipocytes at p21
demonstrate increased lipid accumulation at 40X magnification by
ORO with DAPI staining. *p< 0.05, **p< 0.01.Adipogenic and lipogenic transcription factors adipocyte
phenotype at p21
At baseline, SGA adipocytes continued to show upregu-
lated PPARγ, now accompanied by increased expression
of SREBP1 (Figure 3B).
With rosiglitazone treatment, Control adipocytes
responded to both (low and high) doses, demonstrating
significant increases in PPARγ and SREBP1 expression
(Figure 3B). In contrast, SGA adipocytes responded at
only the higher dose of rosiglitazone treatment with fur-
ther upregulation of PPARγ and SREBP1 expression,
thereby maintaining increased expression over Controls at
only this dose.
After observing that p21 SGA adipocytes were respon-
sive to only the higher dose of rosiglitazone, stable






























Figure 1 Cell proliferation in Control and SGA offspring
preadipocytes. Gray bars represent Controls, and white bars
represent SGA. Cell proliferation decreased with age in both groups.
SGA demonstrated increased cell proliferation compared with
Controls at both p1 and p21, **p< 0.01.Fatty acid metabolism and response to 10 μM
rosiglitazone
Fatty acid profile
At baseline, SGA demonstrated a similar overall fatty
acid profile as compared with Controls (Table 1). In re-
sponse to rosiglitazone, Control, but not SGA adipo-
cytes, increased the stearate percent of total, which
includes preexisting and newly made stearate (Table 1).
FNS over 24 hours
At baseline, SGA had higher new synthesis (FNS) of
palmitate, palmitoleate, stearate, and vaccenate over 24
hours (Figure 4).
In response to rosiglitazone (Figure 4), both Controls
and SGA increased the FNS of palmitate and palmitole-
ate. Notably, Controls decreased the FNS stearate with
rosiglitazone, while SGA did not respond. Overall, SGA
maintained higher FNS rates of these three fatty acids
(palmitate, palmitoleate, and stearate) than Controls.
FASN expression, which was increased at baseline in
SGA, also increased in response to rosiglitazone (Figure 4
inset).
Glucose consumption studies
At baseline, SGA adipocytes consumed more glucose
over 24 hours (Table 2) than Controls. In both groups,
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Rosiglitazone ( M) Rosiglitazone ( M) Rosiglitazone ( M) Rosiglitazone ( M)
Rosiglitazone ( M) Rosiglitazone ( M) Rosiglitazone ( M)
Figure 3 PPARγ and SREBP1 expression by Western blotting in p1 and p21 adipocytes at baseline and with rosiglitazone treatment.
SGA maintained higher expression of PPARγ than Controls at baseline and stimulated states. (A) p1 Control and SGA adipocytes responded to
rosiglitazone at both doses. (B) p21 SGA adipocytes responded only to high dose rosiglitazone. *p< 0.05 compared to untreated cells within the
same group. cp< 0.05 compared to Controls treated with the same dose of rosiglitazone.
Yee et al. Nutrition & Metabolism 2012, 9:62 Page 6 of 11
http://www.nutritionandmetabolism.com/content/9/1/62treatment (Table 2), but increased more in SGA than in
Controls (+interaction).
Acetyl-CoA enrichment
At baseline, SGA demonstrated increased acetyl-CoA
enrichment as well as increased percentage of U13C-Table 1 Profile of major fatty acids, at baseline and with
rosiglitazone
Fatty Acids Percent of Total (%)
Control SGA
Fatty Acid Baseline Rosiglitazone Baseline Rosiglitazone
Palmitate 16:0 36.4 ± 1.5 37.9 ± 1.1 37.5 ± 0.7 37.7 ± 2.4
Palmitoleate 16:1n-7 3.4 ± 0.1 3.09 ± 0.04 3.4 ± 0.1 3.3 ± 0.3
Stearate 18:0 22.6 ± 0.9 29.1 ± 0.9* 20.8 ± 0.6 22.4 ± 1.4c
Oleate 18:1n-9 19.7 ± 0.7 17.4 ± 0.4 20.0 ± 0.3 20.1 ± 1.2
Vaccenate 18:1n-7 12.0 ± 0.5 10.4 ± 0.2 13.2 ± 0.3 12.1 ± 0.9
c p< 0.05 compared with Control receiving the same treatment.
*p< 0.05 compared to the untreated state within the same group.
The fatty acid percentages of total are presented as the mean ± the standard
error of the mean (SEM). With rosiglitazone treatment, Controls demonstrated
increased stearate abundance.glucose contribution to palmitate de novo synthesis
(Figure 5). With rosiglitazone treatment, these measures
were enhanced in both groups, with SGA maintaining
higher levels than Controls. Greater increases were
observed in SGA (+interaction) than in Controls.
TCA cycle activities
To elucidate potential TCA cycle contributions to the
increased acetyl-CoA enrichment, glutamate enrichment
was studied to determine the relative pyruvate carboxyl-
ase and pyruvate dehydrogenase activities. SGA demon-
strated increased entry of U13C-glucose into the TCA
cycle in SGA based on the higher Σmn enrichment
(fraction of 13 C atoms/mole) in both the glutamate C2-4
and C2-5 fragments (Table 3A). SGA demonstrated a
lower PC/PDH ratio as compared with Controls
(Table 3B), suggesting higher PDH activity relative to PC
activity, possibly leading to increased acetyl-CoA pro-
duction for lipogenesis.
In response to rosiglitazone, both groups increased en-




























































































Figure 4 Fraction of new synthesis (FNS) of fatty acids and FASN expression in Controls and SGA at baseline and with 10 μM
rosiglitazone treatment. The data is presented as the mean percentage or mean fold-change in expression± the standard error of the mean.
SGA demonstrated increased FNS palmitate and palmitoleate at baseline and with rosiglitazone when compared to Controls, with a similar
pattern in FASN protein expression (inset). *p< 0.05 compared to untreated state within the same group, cp< 0.05 compared to Controls
receiving the same treatment.
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ratio while SGA increased it to a level similar to Controls
(Table 3B), with a significant interaction between SGA and
rosiglitazone. The increase of the PC/PDH ratio suggested
that SGA shifted its glucose entry to be more balanced be-
tween PC and PDH, but this change could not be attributed
to significant changes in either the PC or PDH enrichment
beyond the changes expected based on the Σmn.
BADGE treatment
At p1, both Control and SGA adipocytes showed moder-
ate decreases in PPARγ and SREBP1 expression at low
dose BADGE, then further decreases with high dose
BADGE. As before, SGA adipocytes continued to exhibit
higher expression of PPARγ (Figure 6A).
At p21, Control and SGA adipocytes differed in their
response to BADGE treatment. While Control adipo-
cytes responded with downregulation of PPARγ and
SREBP1, SGA adipocytes were completely unresponsiveTable 2 Glucose consumption from cell culture medium
in 24 hours at baseline or with rosiglitazone
Glucose Consumption
(mg/mL of culture medium)
Control SGA
Baseline 0.99 ± 0.02 1.23 ± 0.01c
Rosiglitazone Treatment 1.14 ± 0.01* 1.45 ± 0.01*ci
cp< 0.05 compared with Control receiving the same treatment.
*p< 0.05 compared to the untreated state within the same group.
i interaction with rosiglitazone.(Figure 6B). Due to the lack of response, the fatty acid
metabolic studies were not repeated with BADGE.
Discussion
This study demonstrates that SGA adipocytes are intrin-
sically programmed by maternal malnutrition as evident
in the principal findings of: (1) enhanced adipogenesis
through upregulated PPARγ expression, and (2) enhanced
lipogenesis through upregulated SREBP1 and FASN ex-
pression, with increased glucose-mediated fatty acid syn-
thesis. Importantly, SGA adipocytes are overall responsive
to PPARγ activator-ligand, but are selectively responsive at
p21 to the higher dose of PPARγ activator-ligand, with
pathway-specific effects on fatty acid synthesis. In con-
trast, SGA adipocytes at p21 are unresponsive to PPARγ
inhibitor-ligand. Together, these results indicate that the
SGA adipocyte phenotype is programmed in utero, as
demonstrated by enhanced preadipocyte proliferation and
lipid accumulation at p1. Due to resistance to treatment at
p21, therapeutic strategies to prevent the obesogenic adi-
pocyte phenotype should be considered during the nurs-
ing period prior to onset of the resistance.
Consistent with previous studies [24,25], preadipocyte
proliferation declined and adipocyte fat accumulation
amplified with age in both the Control and SGA offspring.
Notably, despite SGA growth-restriction at birth, the SGA
adipose tissue exhibited increased preadipocyte prolifera-
tion with enhanced fat accumulation, consistent with an
obese phenotype. The upregulated transcription factors






























































Figure 5 Acetyl-CoA enrichment and U13C-glucose contribution
to de novo lipogenesis (DNL). Gray bars represent Controls, and
white bars represent SGA. Solid bars represent adipocytes untreated
at baseline, and hatched bars represent adipocytes treated with
10 μM rosiglitazone. (A) SGA adipocytes exhibited increased acetyl-
CoA enrichment, and therefore, (B) increased U13C-glucose
contribution to de novo synthesis of palmitate. There was a
significant interaction between SGA and rosiglitazone for each of
these measures. *p< 0.05 compared to untreated state within the
same group, cp< 0.05 compared to Controls receiving the same
treatment, i interaction with rosiglitazone.
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pogenesis and lipogenesis in SGA offspring. Moreover,
these changes are evident and persistent at postnatal age
p21 in SGA offspring. Increased risk for obesity in SGA
has been well-described, with SGA humans exhibiting
increased visceral adiposity [26] or increased clinical fea-
tures of abdominal adiposity such as waist circumference
[1]. Although obesity may not manifest until adulthood,
our data in nursing SGA pups demonstrating increased
hyperplasia and hypertrophy along with enhanced fatty
acid de novo synthesis indicates the early presence of ab-
normalities that may contribute toward the propensity for
future fat accumulation.
The differential response to rosiglitazone revealed
pathway-specific and age-specific changes in lipogenesisbetween Controls and SGA. Expression of adipogenic
and lipogenic factors was stimulated in both groups at
p1. At p21, however, Controls demonstrated increased
responsiveness with dose increase, while SGA responded
from its basally increased expression to only high-dose
rosiglitazone. The selective response of SGA to the high-
dose rosiglitazone indicates a decline in responsiveness
by the end of the nursing period. Nonetheless, the
decreased responsiveness of SGA at p21 indicated
changes leading toward an obese phenotype as evident
by the fatty acid synthesis data. Further studies are
needed in offspring from p0 to p21 to determine the fac-
tors in the metabolic milieu that may ultimately lead to
p21 rosiglitazone resistance.
In Controls and SGA, rosiglitazone treatment led to
increased FNS of palmitate and palmitoleate, with a
similar pattern of increase in FASN expression. However,
the two groups demonstrated a differential response in
18-carbon stearate synthesis. The Control group increased
its percent of total of stearate in response to rosiglitazone,
despite decreasing the FNS stearate, suggesting decreased
stearate turnover as a normal response to rosiglitazone. In
contrast, SGA adipocytes did not decrease the FNS stear-
ate in response to rosiglitazone, and maintained the new
synthesis rate, suggesting abnormal resistance to modula-
tion in the 18-carbon fatty acid synthesis pathway. The
difference in FNS stearate versus palmitate response to
rosiglitazone supports possibilities of differential regula-
tion and/or compartmentalization of the 16-carbon
versus 18-carbon fatty acid synthesis pathways [20].
Since the FASN expression reflected the FNS palmi-
tate response to rosiglitazone in both groups, the stearate
responses to rosiglitazone are likely mediated by a post-
translational mechanism. Whether these differences in
fatty acid metabolism after rosiglitazone treatment impact
adipocyte function in SGA is not known from our
study, but would be of interest in the setting of long-
term treatment.
Rosiglitazone improves blood glucose control in
humans with diabetes through increased glucose uptake
by muscle and adipose tissue [27]. Therefore, we used
the stable isotope U13C-glucose to determine the rela-
tionship between the fatty acid synthesis pathways and
glucose metabolism in the adipocytes. In fact, our data
demonstrate that SGA adipocytes use more glucose to-
ward fatty acid synthesis (increased acetyl-CoA enrich-
ment). Moreover, SGA demonstrated an augmentation
of response to rosiglitazone (+interaction) possibly through
a programmed increase in sensitivity to glucose abundance.
Correspondingly, SGA demonstrated an increased percent
contribution of U13C-glucose to de novo synthesis with
rosiglitazone treatment. These findings led to investigations
into the PC and PDH-mediated glucose entry pathways
into the TCA cycle.
Table 3 Relative PC and PDH activities determined from adipocyte exposure to U13C-glucose
A.
Σmn C2-4 fragment (mean±SEM) Σmn C2-5 fragment (mean±SEM)
Control SGA Control SGA
Baseline 0.056 ± 0.003 0.073 ± 0.001C 0.060± 0.003 0.084± 0.001C








Control SGA Control SGA Control SGA Control
Baseline 0.015 (0.015-0.017) 0.018 (0.017-0.018) 0.009 (0.009-0.010) 0.017 (0.016-0.018) 1.66 (1.64-1.75) 0.92 (0.90-1.04)C
Rosi Treatment 0.019 (0.018-0.028) 0.025 (0.025-0.026) 0.021 (0.021-0.022 0.021 (0.021-0.022) 1.10 (1.10-1.19)* 1.17 (1.14-1.18)*i
Cp< 0.05 compared with Control receiving the same treatment.
*p< 0.05 compared to the untreated state within the same group.
i interaction between SGA and rosiglitazone.
A) The Σmn representing the average fraction of 13 C atoms/molecule for the C2-4 fragment and C2-5 fragments are shown for cultures with and without
rosiglitazone treatment. The data are presented as fractions of enrichment ± the SEM. Enrichment increased with rosiglitazone treatment in both Controls and
SGA, while SGA maintained higher levels than Controls regardless of treatment. B) The PC and PDH pathway contributions are represented based on glutamate
fragment enrichments. These data are presented as the median with the 25-75% interquartile ranges. At baseline, SGA demonstrated a lower PC/PDH ratio than
Controls. With rosiglitazone, Controls decreased the PC/PDH ratio, while SGA increased it.





































































































Control p21 SGA p21
Control p1 SGA p11
Control p21 SGA p21
BADGE ( M) BADGE ( M)
BADGE ( M)BADGE ( M)BADGE ( M)BADGE ( M)
Figure 6 PPARγ and SREBP1 expression by Western blotting with BADGE treatment. (A) p1, (B) p21. At p21, SGA was resistant to both
doses of BADGE. *p< 0.05 compared to untreated cells within the same group. cp< 0.05 compared to Controls receiving the same dose of
BADGE.
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mine how entry of glucose into the TCA cycle contributed
to the increased acetyl-CoA enrichment in SGA. SGA adi-
pocytes at baseline exhibited a lower PC/PDH ratio than
Controls, suggesting that SGA adipocytes demonstrate
enhanced glucose entry into the TCA cycle to produce
acetyl-CoA for fatty acid synthesis via PDH. Rosiglitazone
treatment led to a decrease in the PC/PDH ratio in Con-
trols, supporting enhanced lipogenesis, while SGA adipo-
cytes unexpectedly demonstrated an increased ratio.
Changes in the separate PC and PDH enrichments were
therefore examined relatively to changes in the Σmn. The
Σmn was increased in SGA at baseline and further
increased with rosiglitazone in both glutamate fragments,
with corresponding trends in PC and PDH m2 enrich-
ment. However, the SGA PC enrichment increased by
39% with rosiglitazone treatment, while the PDH enrich-
ment increased by only 29%, resulting in a net increase in
the PC/PDH ratio. An alternative explanation for the
increased acetyl-CoA enrichment in our study could be
increased recycling of labeled palmitate, through oxidation
and reassembly of labeled acetyl units in de novo synthe-
sis. Additional factors may also be contributing to our
findings, since the turnover of glutamate is low, and the
percentage of glucose contribution to palmitate comprised
only up to 6-12%. The pathway of glucose utilization to
produce palmitate is likely not direct [28], involving other
pathways before these carbons are incorporated into fatty
acids. However, this data illustrates the complex relation-
ship that exists between fatty acid synthesis and glucose
metabolism, which involve multiple metabolic pathways.
Control adipocytes responded to BADGE at both p1
and p21, with further decrease in expression of both
PPARγ and SREBP1 at the high dose. In contrast, SGA
adipocytes demonstrated BADGE resistance at both
doses of rosiglitazone, suggesting that stimulatory factors
that are present cannot be overcome by BADGE at the
experimental doses. It is unknown whether even a
higher dose may have been effective.
Despite the current obesity epidemic, effective strat-
egies for the prevention or treatment of obesity and
related disorders are very limited. SGA adipocytes, previ-
ously adapted to the in utero environment of low energy
resources, suddenly experience a relative nutrient excess
with normal postnatal nutrition [29]. As a result, adipo-
cytes of SGA offspring demonstrate enhanced cell prolif-
eration, and lipogenesis, which may allow SGA offspring
to catch-up in growth. The increased adipogenesis how-
ever, leads to adult obesity and insulin resistance. TZDs
are used to improve insulin sensitivity, but they have also
been studied for their potential to prevent insulin resist-
ance [30,31]. Adipose tissue is the major site of action of
TZDs. Further studies are needed to define the relation-
ship between glucose utilization for fatty acid synthesisand insulin sensitivity, in order to determine if TZDs
may be efficacious in preventing insulin resistance in
SGA. Studies are also needed to determine how the 16-
carbon versus 18-carbon fatty acid synthesis pathways
contribute to adipocyte phenotype in SGA, and whether
differences in response of these pathways to rosiglitazone
may interfere with its potential to prevent insulin resist-
ance. If glucose-mediated lipogenesis contributes to insu-
lin sensitivity in TZD treatment, then risks of further
adipogenesis during TZD therapy must be weighed
against potential benefits of glucose control.
Conclusions
SGA adipocytes at p1 and p21 exhibit enhanced adipo-
genesis and lipogenesis. p1 adipocytes respond to both
activator-ligand and repressor-ligand treatment. How-
ever, p21 SGA adipocytes demonstrate pathway-specific
responses to PPARγ activator-ligand treatment in fatty
acid synthesis. p21 SGA adipocytes are also resistant to
PPARγ repressor-ligand treatment. PPARγ activator-
ligand treatment enhances SGA glucose-mediated lipo-
genesis. The complex relationship between fatty acid
synthesis and glucose metabolic pathways should be fur-
ther investigated in SGA adipocytes.
Abbreviations
SGA: Small-for-gestational age; PPARγ: Peroxisome proliferator-activated
receptor gamma; BADGE: Bisphenol-A diglycidyl ether;
TZD: Thiazolidinedione; ORO: Oil Red O; GC/MS: Gas chromatography/mass
spectrometry; FNS: Fractional synthesis (or fraction of new synthesis);
TCA: Tricarboxylic acid; PC: Pyruvate carboxylase; PDH: Pyruvate
dehydrogenase; SREBP1: Sterol regulatory element binding protein 1;
FASN: Fatty acid synthase; DMEM: Dulbecco’s modified Eagle’s medium;
FBS: Fetal bovine serum; MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; Rosi: Rosiglitazone.
Competing interests
The authors have no competing interests to declare.
Authors’ contributions
JKY participated in the study design, execution, analysis and interpretation of
the fatty acid/stable isotope studies, and also drafted the manuscript. WPL
participated in the fatty acid/stable isotope data analysis and interpretation,
and contributed to manuscript preparation. MGR participated in manuscript
preparation. RHL participated in manuscript preparation. GH established the
adipocyte cultures, performed the MTT assay, ORO staining, and Western
blotting, and contributed to manuscript preparation. JV performed Western
blotting and contributed to manuscript preparation. MD participated in
study design, data analysis and interpretation, and drafting of the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
We appreciate Linda Day, Stacy Behare, and Catherine S. Mao for their
assistance in animal care. We thank Shu Lim and Paulin Wahjudi for technical
assistance in glutamate analysis. J.K.Y. is supported by grant K23 DK083241
from the NIDDK and the Clinical Scholar Award from the Pediatric Endocrine
Society. M.D. is supported by grant R01DK081756 from the NIDDK. The GC/
MS analyses were performed at the LABioMed at Harbor-UCLA Biomedical
Mass Spectrometry Facility, which is supported by the UCLA CTSI through
grant 1UL1-RR033176.
Author details
1Department of Pediatrics, Division of Endocrinology, Los Angeles Biomedical
Research Institute at Harbor-UCLA Medical Center, David Geffen School of
Yee et al. Nutrition & Metabolism 2012, 9:62 Page 11 of 11
http://www.nutritionandmetabolism.com/content/9/1/62Medicine at UCLA, 1000 West Carson Street, Harbor Box 446, Torrance, CA
90509, USA. 2Department of Obstetrics and Gynecology, Los Angeles
Biomedical Research Institute at Harbor-UCLA Medical Center, David Geffen
School of Medicine at UCLA, 1000 West Carson Street, Harbor Box 446,
Torrance, CA 90509, USA. 3Division of Neonatology, University of Utah School
of Medicine, Williams Building, P.O. Box 581289, Salt Lake City, UT 84158,
USA.
Received: 12 April 2012 Accepted: 14 June 2012
Published: 22 June 2012References
1. Ravelli AC, van Der Meulen JH, Osmond C, Barker DJ, Bleker OP: Obesity at
the age of 50 y in men and women exposed to famine prenatally. Am J
Clin Nutr 1999, 70:811–816.
2. Ravelli GP, Stein ZA, Susser MW: Obesity in young men after famine
exposure in utero and early infancy. N Engl J Med 1976, 295:349–353.
3. Yee JK, Lee WN, Han G, Ross MG, Desai M: Organ-specific alterations in
fatty acid de novo synthesis and desaturation in a rat model of
programmed obesity. Lipids Health Dis 2011, 10:72.
4. Desai M, Gayle D, Babu J, Ross MG: Programmed obesity in intrauterine
growth-restricted newborns: modulation by newborn nutrition. Am J
Physiol Regul Integr Comp Physiol 2005, 288:R91–R96.
5. Desai M, Gayle D, Babu J, Ross MG: The timing of nutrient restriction
during rat pregnancy/lactation alters metabolic syndrome phenotype.
Am J Obstet Gynecol 2007, 196:e551–e557.
6. Desai M, Gayle D, Han G, Ross MG: Programmed hyperphagia due to
reduced anorexigenic mechanisms in intrauterine growth-restricted
offspring. Reprod Sci 2007, 14:329–337.
7. Desai M, Guang H, Ferelli M, Kallichanda N, Lane RH: Programmed
upregulation of adipogenic transcription factors in intrauterine growth-
restricted offspring. Reprod Sci 2008, 15:785–796.
8. Kim JB, Spiegelman BM: ADD1/SREBP1 promotes adipocyte differentiation
and gene expression linked to fatty acid metabolism. Genes Dev 1996,
10:1096–1107.
9. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz
BG, Lachin JM, O'Neill MC, Zinman B, Viberti G: Glycemic durability of
rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006,
355:2427–2443.
10. Albrektsen T, Frederiksen KS, Holmes WE, Boel E, Taylor K, Fleckner J: Novel
genes regulated by the insulin sensitizer rosiglitazone during adipocyte
differentiation. Diabetes 2002, 51:1042–1051.
11. Muhlhausler BS, Morrison JL, McMillen IC: Rosiglitazone increases the
expression of peroxisome proliferator-activated receptor-gamma target
genes in adipose tissue, liver, and skeletal muscle in the sheep fetus in
late gestation. Endocrinology 2009, 150:4287–4294.
12. Kim SK, Park CK, Lee SY, Song JS, Park SH, Kim YK: Effects of Rosiglitazone
on the Expression of PPAR-gamma and the Production of IL-6 and IL-8
in Acute Lung Injury Model Using Human Pulmonary Epithelial Cells.
Trop J Pharm Res 2011, 10:559–566.
13. Johnson JA, Trasino SE, Ferrante AW Jr, Vasselli JR: Prolonged decrease of
adipocyte size after rosiglitazone treatment in high- and low-fat-fed rats.
Obesity (Silver Spring) 2007, 15:2653–2663.
14. Ye JM, Dzamko N, Cleasby ME, Hegarty BD, Furler SM, Cooney GJ, Kraegen
EW: Direct demonstration of lipid sequestration as a mechanism by
which rosiglitazone prevents fatty-acid-induced insulin resistance in the
rat: comparison with metformin. Diabetologia 2004, 47:1306–1313.
15. Oakes ND, Thalen PG, Jacinto SM, Ljung B: Thiazolidinediones
increase plasma-adipose tissue FFA exchange capacity and enhance
insulin-mediated control of systemic FFA availability. Diabetes 2001,
50:1158–1165.
16. Wright HM, Clish CB, Mikami T, Hauser S, Yanagi K, Hiramatsu R, Serhan CN,
Spiegelman BM: A synthetic antagonist for the peroxisome proliferator-
activated receptor gamma inhibits adipocyte differentiation. J Biol Chem
2000, 275:1873–1877.
17. Kota BP, Huang TH, Roufogalis BD: An overview on biological mechanisms
of PPARs. Pharmacol Res 2005, 51:85–94.
18. Lowenstein JM, Brunengraber H, Wadke M: Measurement of rates of
lipogenesis with deuterated and tritiated water. Methods Enzymol 1975,
35:279–287.19. Lee WN, Byerley LO, Bergner EA, Edmond J: Mass isotopomer analysis:
theoretical and practical considerations. Biol Mass Spectrom 1991,
20:451–458.
20. Yee JK, Mao CS, Hummel HS, Lim S, Sugano S, Rehan VK, Xiao G, Lee WN:
Compartmentalization of stearoyl-coenzyme A desaturase 1 activity in
HepG2 cells. J Lipid Res 2008, 49:2124–2134.
21. Lee WN, Edmond J, Bassilian S, Morrow JW: Mass isotopomer study of
glutamine oxidation and synthesis in primary culture of astrocytes. Dev
Neurosci 1996, 18:469–477.
22. Des Rosiers C, Lloyd S, Comte B, Chatham JC: A critical perspective of the
use of (13)C-isotopomer analysis by GCMS and NMR as applied to
cardiac metabolism. Metab Eng 2004, 6:44–58.
23. Bartnik BL, Hovda DA, Lee PW: Glucose metabolism after traumatic brain
injury: estimation of pyruvate carboxylase and pyruvate dehydrogenase
flux by mass isotopomer analysis. J Neurotrauma 2007, 24:181–194.
24. Kirkland JL, Hollenberg CH, Gillon WS: Age, anatomic site, and the
replication and differentiation of adipocyte precursors. Am J Physiol 1990,
258:C206–C210.
25. Honma T, Yanaka M, Tsuduki T, Ikeda I: Increased lipid accumulation in
liver and white adipose tissue in aging in the SAMP10 mouse. J Nutr Sci
Vitaminol (Tokyo) 2011, 57:123–129.
26. Ibanez L, Lopez-Bermejo A, Suarez L, Marcos MV, Diaz M, de Zegher F:
Visceral adiposity without overweight in children born small for
gestational age. J Clin Endocrinol Metab 2008, 93:2079–2083.
27. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 2004, 351:1106–1118.
28. Collins JM, Neville MJ, Pinnick KE, Hodson L, Ruyter B, van Dijk TH,
Reijngoud DJ, Fielding MD, Frayn KN: De novo lipogenesis in the
differentiating human adipocyte can provide all fatty acids necessary for
maturation. J Lipid Res 2011, 52:1683–1692.
29. Gluckman PD, Hanson MA: Living with the past: evolution, development,
and patterns of disease. Science 2004, 305:1733–1736.
30. Hevener AL, Reichart D, Janez A, Olefsky J: Thiazolidinedione treatment
prevents free fatty acid-induced insulin resistance in male wistar rats.
Diabetes 2001, 50:2316–2322.
31. Chung SS, Kim M, Youn BS, Lee NS, Park JW, Lee IK, Lee YS, Kim JB, Cho YM,
Lee HK, Park KS: Glutathione peroxidase 3 mediates the antioxidant effect
of peroxisome proliferator-activated receptor gamma in human skeletal
muscle cells. Mol Cell Biol 2009, 29:20–30.
doi:10.1186/1743-7075-9-62
Cite this article as: Yee et al.: Peroxisome proliferator-activated receptor
gamma modulation and lipogenic response in adipocytes of small-for-
gestational age offspring. Nutrition & Metabolism 2012 9:62.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
